3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SkyAI, Inc. said it will begin its previously announced cash tender offer on October 15, 2026, when it files a Schedule TO with the SEC after market close. The offer seeks up to 95% of each class of shares and warrants at $3.00 each, a price the company says is a 65% premium to its October 9, 2026 closing share price, and the company expects to hold no SOL once the offer is completed.
Purchase price of $3.00 per share or warrant in cash, a 65% premium to the October 9, 2026 closing share price
Offer expires at one minute after 11:59 p.m. New York City time on October 29, 2026, unless extended or terminated earlier
As of October 14, 2026, the company held about $204.6 million in cash and about 210,000 locked SOL, and sold SOL at an average of $107.51 net of fees
Ocugen signed an exclusive license agreement with Roots Pharmaceutical Company on October 13, 2026, for its OCU400 gene therapy for retinitis pigmentosa in certain Middle East and North Africa countries. Ocugen will receive up to $4 million in upfront and development payments, up to $255 million in sales milestones, and a 22% royalty on Roots' net sales, and will also supply the product under a separate agreement. On the same day, the board postponed the Special Meeting of Stockholders on the proposal to increase authorized common shares by 250,000,000 to December 22, 2026.
Up-front license fee and development milestones of up to $4 million in aggregate
Sales milestone payments of up to $255 million and a 22% royalty on net sales in the Territory
Special Meeting on the authorized share increase postponed to December 22, 2026; new record date is October 30, 2026
Zone Frontier sold its legacy CleanCore cleaning products business, including its Irish subsidiary, to Sanzonate Holdings LLC under an agreement signed and closed on October 7, 2026. Director Clayton Adams controls the buyer, and the transaction was approved by disinterested directors after a fairness opinion from Newbridge Securities Corporation. The company says the sale ends about $3 million in annual cash burn, but it also takes on credit risk from a buyer that is paying mostly through a secured note.
Buyer Sanzonate Holdings LLC is controlled by Clayton Adams, a Zone Frontier director and the buyer's CEO.
Purchase price is $3,350,000, paid by a secured, non-convertible 6% promissory note due in installments at six, 12 and 18 months after closing.
Up to $2,250,000 in earnout payments depends on buyer equity financings at $10 million, $17.5 million and $25 million pre-money valuations, and the company receives a 5% membership interest in the buyer.
The pro forma statements show an estimated gain on sale of $885,579 as of June 30, 2026; the company's 10-K auditor flagged substantial doubt about its ability to continue as a going concern.
Mannatech told investors it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, after a deficiency notice dated April 20, 2026. The claim rests on a pro forma adjustment tied to a share purchase agreement and a tax ruling, and the auditor review and Nasdaq's own view are still pending, so the listing outcome remains uncertain for shareholders.
Stockholders' equity was $(5,223,000) per the 2025 Form 10-K and $(4,970,000) as of June 30, 2026, per the Q2 Form 10-Q, against a $2,500,000 requirement.
Mannatech's share purchase agreement gives it 100% direct ownership of Mannatech Swiss Holdings GmbH, which the company says qualifies distributions for a 5% withholding tax rate.
Nasdaq will keep monitoring; if the 10-K for the year ending December 31, 2026 does not show compliance, the company may face delisting, with a right to appeal to a Nasdaq Hearings Panel.
The Q3 2026 Form 10-Q is expected on or before November 16, 2026, and the pro forma adjustment will be reviewed by the independent auditor.
Comtech reported results for fiscal 2026, ended July 31, 2026, with net sales down 17.0% to $249.6 million as legacy U.S. Army contracts wound down. The net loss from continuing operations attributable to common stockholders narrowed to $51.0 million from $67.9 million, and adjusted EBITDA rose 26% to $20.6 million, while the fourth-quarter net loss widened slightly to $9.4 million. The results cover continuing operations only, excluding the S&S business that Comtech agreed to sell to a Gilat affiliate for $157.5 million, a deal expected to close in calendar 2026.
Fiscal 2026 net sales were $249.6 million, down 17.0% from $300.9 million in fiscal 2025.
Fiscal 2026 net loss from continuing operations attributable to common stockholders was $51.0 million, compared with $67.9 million a year earlier.
Adjusted EBITDA rose 26% to $20.6 million, and operating cash flow was $25.0 million versus cash used of $29.2 million in fiscal 2025.
Fourth-quarter net sales were $66.2 million, down 12.1%, and the fourth-quarter net loss was $9.4 million versus $9.1 million a year earlier.
Elite Express Holding Inc. (ETS) reported results for the quarter ended August 31, 2026, with revenue up 20.9% and gross profit rising to $95,759 from $6,817. Net loss widened to $760,138 from $185,881 a year earlier, mainly because general and administrative expenses rose $865,424 to $1,017,024. For shareholders, the top-line and gross profit gains were offset by a larger loss driven by higher overhead.
Revenue was $766,422 for the quarter, up 20.9% from $633,865 a year earlier.
Gross profit was $95,759, up from $6,817, with gross margin at 12.5% versus 1.1%.
General and administrative expenses rose to $1,017,024, including $586,252 in higher payroll and $137,337 in higher professional fees.
Net loss was $760,138, or $0.02 per share, compared with a net loss of $185,881, or $0.01 per share, a year earlier.
Netcapital regained compliance with the Nasdaq minimum bid price rule after its closing bid price was at or above $1.00 for 10 consecutive business days, from September 23 through October 6, 2026, and Nasdaq closed the matter. The company engaged Adeptus Partners, LLC to re-audit fiscal years 2022 through 2026 because its previously issued financial statements for fiscal 2022 through 2025 should no longer be relied upon, and it has not finished evaluating the corrections that may be required. The company remains out of compliance with Nasdaq Listing Rule 5250(c)(1) for not filing its late annual and quarterly reports, so listing risk on that matter continues until a plan is accepted.
Nasdaq closed the bid price deficiency after the closing bid price was at or above $1.00 for 10 consecutive business days, September 23 through October 6, 2026.
Still out of compliance with Rule 5250(c)(1) for not filing the Form 10-K for fiscal year ended April 30, 2026 or the Form 10-Q for quarter ended July 31, 2026; plan due October 23, 2026.
Adeptus Partners, LLC engaged, with the Audit Committee approving on October 8, 2026, succeeding Fruci & Associates II, PLLC, which resigned effective August 12, 2026.
Financial statements for fiscal years 2022 through 2025 should no longer be relied upon; the scope of any restatement has not been determined.
Daktronics approved a manufacturing network optimization that includes a phased exit from its Ennistymon, Ireland facility and an exit from the highly customized portions of its international transportation business. The company expects $15.8 million in non-recurring pre-tax charges, with about $7.0 million in the current fiscal quarter, and more than $18.0 million in annualized run-rate savings once the actions are fully implemented by mid-fiscal 2028.
Ireland phased exit expected to be substantially complete in the first half of fiscal 2028, with about $13.5 million of cumulative charges
Total charges of $15.8 million, about $7.0 million of which falls in fiscal 2027 Q2
Annualized run-rate savings of more than $18.0 million when fully implemented, expected by mid-fiscal 2028
Separate 8-K Item 8.01 corrects a clerical error in the September 2, 2026 Form 10-Q, which showed fiscal 2027 capital expenditures of $13.2 million; the intended estimate was $23.4 million
USBC signed a Second Addendum on October 12, 2026 that raises the borrowing commitment under its Master Loan Agreement with Payward Interactive, Inc. from $25.0 million to $40.0 million, with $21.0 million outstanding and $19.0 million available. The company also amended its collateral arrangement so Bitcoin collateral can secure both loan obligations and certain digital asset derivative transactions, which ties more obligations to the same collateral and could lead to liquidation of that collateral if specified defaults occur.
Commitment rises from $25.0 million to $40.0 million under the Master Loan Agreement dated March 18, 2026, amended by the Second Addendum dated October 12, 2026.
$21.0 million principal outstanding; $19.0 million available, subject to borrowing conditions and collateral requirements.
Account control agreement amended to cross-collateralize MLA obligations and certain digital asset derivative transactions; collateral may be applied after specified defaults.
Virtual 2026 Annual Meeting set for December 17, 2026; record date October 26, 2026; stockholder proposal and nomination notices due October 23, 2026.
Progressive reported September 2026 net income of $630 million, up from $305 million a year earlier, with diluted earnings of $1.08 per share versus $0.52. For the September quarter, net income fell 3% to $2.54 billion and earnings per share fell 2% to $4.37, as pretax realized investment losses offset stronger premium growth.
September net premiums written rose 2% to $7.26 billion and net premiums earned rose 5% to $7.16 billion.
September combined ratio was 90.0 versus 100.4 a year earlier; the quarterly combined ratio was 88.7 versus 89.5.
Quarterly net income was $2.54 billion, down 3% from $2.62 billion; pretax realized losses on securities were $170 million for the quarter, versus $295 million of gains a year earlier.
SKYX Platforms completed its merger with Deako, Inc. on October 13, 2026, making Deako a wholly-owned subsidiary. The Company issued 25,000,000 shares, which existing SKYX shareholders will own about 84.4% of post-merger, with Deako's former holders owning about 15.6%, and also took on an $8,500,000 senior secured promissory note at 12.0% interest. The share issuance adds substantial dilution for current shareholders, and the note adds a debt obligation, the Company's ability to repay which is listed as a risk factor.
Merger with Deako, Inc. closed October 13, 2026; 25,000,000 unregistered common shares issued
Post-merger ownership: current SKYX shareholders about 84.4%, former Deako shareholders about 15.6%
Senior secured promissory note of $8,500,000 at 12.0% per annum; $2,250,000 due 120 days after closing, remainder due at 12 months
Merger Shares subject to 12-month lock-up, with 25% released at 12, 15, 18 and 21 months after closing
Coya Therapeutics plans to start an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS in November 2026, in response to requests from investigators and participants. To prioritize the ALS program, the company now expects its Phase 2 trial of COYA 302 in frontotemporal dementia to start in 2027 rather than the second half of 2026, while its cash runway guidance is unchanged.
Open-label extension expected to begin in November 2026, as the first cohort completes the 48-week treatment period
Phase 2 trial in frontotemporal dementia now expected in 2027, previously anticipated in the second half of 2026
Cash resources expected to fund operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout
ALSTARS trial to randomize approximately 120 subjects; primary endpoint is change in ALSFRS-R total score at Week 24 versus placebo
Flex completed its $4.4 billion cash acquisition of EPC Power on October 14, 2026, and is now part of its Cloud and Power Infrastructure business. The purchase was funded with a $3.3 billion Credit Facility, a $1.1 billion Bridge Credit Facility and cash on hand, both facilities maturing October 13, 2027. Repayment depends in part on the pending $2.0 billion Axiom preferred investment and the planned first-quarter 2027 spin-off of that business.
Purchase price was $4.4 billion in cash, subject to customary adjustments, with a locked box date of June 30, 2026.
The Company borrowed $3.3 billion under its Credit Facility and $1.1 billion under its Bridge Credit Facility on October 14, 2026.
Both facilities mature on October 13, 2027, and the Credit Facility must be prepaid when Axiom funds a term loan tied to the spin-off.
Axiom's $2.0 billion Series A Convertible Preferred Stock investment has not closed and is subject to regulatory conditions; Axiom expects to use the proceeds to repay Transaction borrowings.
Entrada Therapeutics said Cohort 1 of its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in Duchenne muscular dystrophy met its primary safety and tolerability objectives at a 5 mg/kg dose. Secondary results showed a 0.10% mean increase in dystrophin production from baseline in treated participants versus a 0.02% mean decrease in placebo, and the company said no observable functional benefit was expected or seen after three doses. The data are early and small, with eight participants in the cohort, and Cohort 2 data at 10 mg/kg are expected in the first half of 2027.
Cohort 1 enrolled eight participants randomized 3:1 to ENTR-601-45 at 5 mg/kg or placebo, dosed on days one, 43 and 85.
Mean dystrophin increase of 0.10% from baseline (n = 6, nominal p = 0.03) versus a 0.02% mean decrease for placebo.
Headache (5 events in 2 participants) was the most common treatment-emergent adverse event; no study discontinuations occurred.
Cohort 2 (10 mg/kg) data are expected in the first half of 2027, with Cohort 3 (up to 15 mg/kg) to follow.
On October 12, 2026, Faraday Future signed a Transaction Agreement under which FFR, a company it controls, will acquire its robotics business for a purchase price of $200 million, paid in FFR common and non-voting preferred stock. Because FFR is controlled by the company, the deal is a related-party transaction, and closing depends on conditions including FFR stockholder approval, with an outside date of December 31, 2026.
Purchase price of $200,000,000, adjusted for outstanding FF Robotics options, paid at $2.246 per FFR share
At closing, FFR issues 1,317,949 common shares and 65,427 non-voting convertible preferred shares to the Cayman Seller
Company expects FFAI to hold approximately 65.7% of FFR after closing, with closing expected by the end of October 2026
FFR plans a PIPE financing of up to $10 million, but closing is not conditioned on it
On October 12, 2026, FF EAI Robotics Ecosystem agreed to acquire the robotics business of Faraday Future Intelligent Electric (FFAI), its majority stockholder, in a transaction valued at US$200 million and paid mostly in newly issued shares. Because FFAI controls the company, a special committee of independent directors reviewed the deal and a fairness opinion was obtained, but the issuance will substantially dilute existing shareholders.
Transaction Agreement signed October 12, 2026 with FFAI, Smart Technology Holdings Ltd. and others; the board approved it on the special committee's recommendation.
Preferred shares cannot be converted until stockholder approval is obtained; the company plans written consent and a Schedule 14C information statement after closing.
The 8-K describes a possible private placement of no more than US$30 million, while the press release says up to $10 million; the press release also says closings are expected by the end of October 2026.
Sono-Tek reported fiscal second-quarter and first-half 2027 results for the period ended August 31, 2026. First-half net sales rose 6% to $10.89 million and first-half net income rose 22% to $1.11 million, but second-quarter net income fell 14% to $366,000 on higher operating expenses. The company reiterated its fiscal 2027 guidance of flat to modest revenue growth and reported backlog of $9.51 million, with three orders totaling about $7.19 million received after quarter end.
First-half net sales rose 6% to $10.89 million; second-quarter net sales rose 1% to $5.23 million.
Second-quarter net income was $366,000, or $0.02 per diluted share, versus $424,000, or $0.03, a year earlier.
Backlog was $9.51 million at August 31, 2026; three orders totaling about $7.19 million were received after quarter end and are expected to ship in fiscal 2028.
Fiscal 2027 revenue guidance of flat to modest growth was reiterated; cash and marketable securities totaled $17.7 million with no outstanding debt.
Bank of America reported third-quarter 2026 net income of $6.9 billion, or $0.91 per diluted share, down from $8.3 billion, or $1.04, a year earlier. The results include a $1.2 billion regulatory settlement charge, or $0.17 per share, tied to consent orders over its Bank Secrecy Act and anti-money laundering compliance programs, which shareholders should weigh against the underlying revenue growth of 3%.
Q3 2026 net income $6.9 billion, EPS $0.91, versus $8.3 billion and $1.04 in Q3 2025
Excluding the $1.2 billion regulatory settlement charge, adjusted EPS was $1.08 and adjusted net income was $8.1 billion
Revenue rose 3% to $30.0 billion; net interest income rose 8% to $16.4 billion
Returned $8.3 billion to shareholders: $2.2 billion in dividends and $6.0 billion in buybacks
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.